A Phase 3 interventional study of Methotrexate and Placebo in Moderate to Severe Atopic Dermatitis, sponsored by medac GmbH. Recruiting at 30 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-27.
Sponsored by medac GmbH · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 159 studies in Dermatitis, Atopic with a site in Poland — 12 open to participants now, 32 under way, 10 of them phase 3. Dermatitis, Atopic · Poland.
Among the 159 studies in Dermatitis, Atopic with a site in Poland, this one is the 69th largest by planned enrollment of the 151 interventional ones that give a count, is one of 14 that started in 2024, is one of 60 in phase 3, reaches primary completion later than 10 of the 31 other live ones, and was the 121st registered.
1,595 studies on the registry are indexed under Dermatitis, Atopic; 288 are open to participants now.
Browse Dermatitis, Atopic studies →12 of the 159 studies in Dermatitis, Atopic with a site in Poland are open now. Recruiting first, the newest first:
Apollo Therapeutics Ltd · Sites in Poland, United States, Bulgaria and 5 more countries
Ages 18–65
Pfizer · Sites in Poland, United States, China and 4 more countries
Ages 2–11
Pfizer · Sites in Poland, United States, Bulgaria and 6 more countries
Ages 18–64
Novartis Pharmaceuticals · Sites in Poland, United States, Argentina and 14 more countries
Ages 18–100
Apogee Therapeutics, Inc. · Sites in Poland, United States, Canada and 6 more countries
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
159 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 72 · Phase 3 63 · Phase 4 2
First in 1998; this study’s year is marked. 14 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 277 is above the median of 82 across 1,249 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 250 across the 151 interventional studies, 800 across the 7 observational. Of the 124 that completed or were terminated, 85 (69%) have results posted.
This tab as a report to print or save as PDF → With an account.
148 of 159 have an industry lead sponsor. The 10 most frequent:
medac GmbH is the lead sponsor of 22 studies on the registry; 2 are open to participants now.
medac GmbH has 1 study filed under Dermatitis, Atopic — fewer than ten, so there is no comparison to draw.
12 of the studies in Dermatitis, Atopic with a site in Poland that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06239311Phase 3medac GmbHEfficacy and Safety of Methotrexate Versus Placebo in Adults With Atopic Dermatitis. | 2026-11 |
| NCT06241118Phase 3SanofiA Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor | 2027-09-30 |
| NCT06395948Apogee Therapeutics, Inc.A Study Evaluating APG777 in Atopic Dermatitis | 2026-11 |
| NCT07230860Janssen Research & Development, LLCA Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis | 2026-11-19 |
| NCT07105488Bluefin Biomedicine, Inc.A Study Evaluating BFB759 in Moderate to Severe Atopic Dermatitis | 2027-02-28 |
Add all 12 to your calendar (.ics) → With an account.
Among the 159 studies in Dermatitis, Atopic with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Atopic dermatitis is an ongoing condition that causes skin irritation, redness, and itchiness. Treatments are usually topical - applied to the skin (e.g., moisturisers or medicated creams) - but a wider variety of systemic treatments (that target the whole body) are needed for those whose condition does not improve with topical treatments. Methotrexate, a drug approved for similar conditions such as arthritis and psoriasis, has been shown to improve atopic dermatitis. This randomised, controlled clinical trial will investigate how effective.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Presenting serious, acute or chronic infections such as tuberculosis, or C, positive, or other immunodeficiency syndromes
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive 16 to 24 weekly subcutaneous injections of 20 mg . In case of intolerance of the 20 mg dose, a reduction to 15 mg per week is possible.
Drug: Methotrexate
Participants will receive 16 to 24 weekly subcutaneous injections
Drug: Placebo
Solution for injection in prefilled pen
Solution for injection in prefilled pen
Eczema Area and Severity Index (EASI) 75 response at Trial Week 16 Visit
To demonstrate the superiority of subcutaneous (SC) methotrexate (MTX) versus placebo with respect to an improvement from baseline of at least 75% of the Eczema Area and Severity Index (EASI 75 response). The Eczema Area and Severity Index (EASI) is an investigator-assessed instrument for measuring the severity of clinical symptoms in atopic dermatitis (AD). The minimum EASI score is 0 (= normal) and the maximum EASI score is 72 (= very severe).
Time frame: Trial Week 16
Improvement from baseline of at least 50% in the Eczema Area and Severity Index (EASI 50 response)
The Eczema Area and Severity Index (EASI) is an investigator-assessed instrument for measuring the severity of clinical symptoms in atopic dermatitis (AD). The minimum EASI score is 0 (= normal) and the maximum EASI score is 72 (= very severe).
Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16
Improvement from baseline of at least 75% in the Eczema Area and Severity Index (EASI 75 response)
The Eczema Area and Severity Index (EASI) is an investigator-assessed instrument for measuring the severity of clinical symptoms in AD. The minimum EASI score is 0 (= normal) and the maximum EASI score is 72 (= very severe).
Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 24
Improvement from baseline of at least 90% in the Eczema Area and Severity Index (EASI 90 response)
The Eczema Area and Severity Index (EASI) is an investigator-assessed instrument for measuring the severity of clinical symptoms in atopic dermatitis (AD). The minimum EASI score is 0 (= normal) and the maximum EASI score is 72 (= very severe).
Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16
Change from baseline in the Eczema Area and Severity Index (EASI) score.
The Eczema Area and Severity Index (EASI) is an investigator-assessed instrument for measuring the severity of clinical symptoms in atopic dermatitis (AD). The minimum EASI score is 0 (= normal) and the maximum EASI score is 72 (= very severe).
Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16
Scoring Atopic Dermatitis (SCORAD) 50 response
Response is defined as an improvement from baseline of at least 50%. The Scoring Atopic Dermatitis (SCORAD) evaluates the extent and severity of eczema in atopic dermatitis (AD) based on affected body area and intensity of plaque characteristics.It comprises 3 areas: Area, Intensity and Subjective Symptoms. The final result range is between 0 (best result) and 103 (worst result).
Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16
Scoring Atopic Dermatitis (SCORAD) 75 response
Response is defined as an improvement from baseline of at least 75%. The Scoring Atopic Dermatitis (SCORAD) evaluates the extent and severity of eczema in atopic dermatitis (AD) based on affected body area and intensity of plaque characteristics.It comprises 3 areas: Area, Intensity and Subjective Symptoms. The final result range is between 0 (best result) and 103 (worst result).
Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16,
Change in Scoring Atopic Dermatitis (SCORAD) score from baseline
The Scoring Atopic Dermatitis (SCORAD) evaluates the extent and severity of eczema in atopic dermatitis (AD) based on affected body area and intensity of plaque characteristics.It comprises 3 areas: Area, Intensity and Subjective Symptoms. The final result range is between 0 (best result) and 103 (worst result).
Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16
Investigator Global Assessment (IGA) response
Investigator Global Assessment (IGA) response is defined as either an IGA score of 0 (clear) or 1 (almost clear) and a reduction of the score of at least 2 points. The IGA score is a 5-point scale with morphologic descriptors for each score to assess the severity of atopic dermatitis from 0 - Clear 4 - Severe.
Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16, Trial Week 24
Pruritus Numerical Rating Scale (NRS) response
The Pruritus Numerical Rating Scale (NRS) response is defined as a decrease of the worst daily Pruritus NRS score from baseline by at least 4 points in participants with an NRS of at least 4 points at baseline. The NRS is a single item designed to capture information on self-reported severity of worst itching each day on an 11-point scale from 0 ("no itch") to 10 ("worst itch imaginable").
Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16, Trial Week 24
Change from baseline in Pruritus Numerical Rating Scale (NRS) score
The Pruritus Numerical Rating Scale (NRS) is a single item designed to capture information on self-reported severity of worst itching each day on an 11-point scale from 0 (no itch) to 10 (worst itch imaginable).
Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16
Patient-oriented Eczema Measure (POEM) response
Patient-oriented Eczema Measure (POEM) response is defined as reduction from baseline of at least 4 points. The POEM is a seven-item, patient-reported questionnaire assessing atopic dermatitis (AD)/eczema-specific symptoms over the last week; each item is scored 0 (no days) to 4 (every day) based on the number of days affected. The minimum POEM score is 0 (best result) and the maximum total POEM score is 28 (worst result).
Time frame: Trial Week 8, Trial Week 16
Change from baseline in POEM score
The POEM is a seven-item, patient-reported questionnaire assessing atopic dermatitis (AD)/eczema-specific symptoms over the last week; each item is scored 0 (no days) to 4 (every day) based on the number of days affected. The minimum POEM score is 0 (best result) and the maximum total POEM score is 28 (worst result).
Time frame: Trial Week 8, Trial Week 16
Adverse events (AE), treatment-related AEs, serious adverse events (SAEs) and serious adverse reactions (SARs)
For participants who have not reached EASI 50 by the Trial Week 16 Visit and do not enter the extension phase: Adverse events (AE), treatment-related AEs, serious adverse events (SAEs) occurring from the Screening Visit until Trial Week 16 Visit, and serious adverse reactions (SARs) occurring from start of the trial intervention until the Trial Week 20 Visit For participants who do reach EASI 50 by the Trial Week 16 Visit and do enter the extension phase: AEs, treatment-related AEs, SAEs occurring from the Screening Visit until End of Extension Visit (Trial Week 24), and SARs occurring from start of the trial intervention until the Follow-up Visit (Trial Week 33)
Time frame: Trial Week 16, Trial Week 20, Trial Week 24, Trial Week 33
Dermatology Life Quality Index (DLQI) response
Dermatology Life Quality Index (DLQI) response is defined as reduction of at least 4 points in DLQI from baseline. The DLQI is a 10-item questionnaire assessing health-related quality of life over the last week in patients with dermatological symptoms, with each item scored for impact from not at all (0) to very much (3).
Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16
Change from baseline in Dermatology Life Quality Index (DLQI) score.
The Dermatology Life Quality Index (DLQI) is a 10-item questionnaire assessing health-related quality of life over the last week in patients with dermatological symptoms, with each item scored for impact from not at all (0) to very much (3).
Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16
Change from baseline in Scoring Atopic Dermatitis (SCORAD) sleep score
Scoring Atopic Dermatitis (SCORAD) sleep score is a subset of the SCORAD related to the subjective symptoms section (insomnia) sleeplessness will be evaluated by the participant (based on the quality of life in the past 3 days). A 10 cm visual analogue scale is used, with 0 for no symptom and 10 for most severe symptom.
Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16
Change from baseline in Work Productivity and Activity Impairment: General Health (WPAI:GH)
The Work Productivity and Activity Impairment: General Health (WPAI:GH) questionnaire consists of 6 questions assessing the effect of AD (including physical and emotional problems or symptoms) on the participant's ability to work and to perform regular activities. The questions are computed according to specific calculation rules and have four scores. High scores indicate prolonged sick leave or impairment and decreased productivity.
Time frame: Trial Week 8, Trial Week 16
Change from baseline in Hospital Anxiety and Depression (HADS) score and subscales
Hospital Anxiety and Depression (HADS) is a fourteen-item scale with seven items each for anxiety and depression subscales. Each subscale can score between 0 (best result) and 21 (worst result) for either anxiety or depression.
Time frame: Trial Week 8, Trial Week 16
Change from baseline in European Quality of Life (EuroQoL) Group 5 Dimension 5 Levels (EQ-5D-5L)
The European Quality of Life (EuroQoL) Group 5 Dimension 5 Levels (EQ-5D-5L) consists of 2 pages: the EQ-5D descriptive system and the EQ visual analogue scale (EQ VAS). The descriptive system comprises 5 dimensions, each dimension has 5 levels. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the 5 dimensions can be combined into a 5-digit number ranging from 11111 (full health) to 55555 (worst health). The EQ VAS records the participant's self-rated health on a vertical visual analogue scale from 0 (The worst health you can imagine) to 100 (The best health you can imagine).
Time frame: Trial Week 8, Trial Week 16
Change from baseline in Atopic Dermatitis Control Tool (ADCT) score
The Atopic Dermatitis Control Tool (ADCT) is a validated tool to evaluate the different dimensions of patient-perceived atopic dermatitis (AD) control. It consists of 6 questions, each scored from 0 to 4. The minimum total ADCT score is 0 (best result) and the maximum total ADCT score is 24 (worst result).
Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16
Eczema Area and Severity Index (EASI) 75 response at Trial Week 24 and the Follow-up Visit (Week 33)
The Eczema Area and Severity Index (EASI) response in those participants who had an EASI 75 response at Trial Week 24 and did not need any systemic treatment for AD (relapse) until the Follow-up Visit. The EASI is an investigator-assessed instrument for measuring the severity of clinical symptoms in atopic dermatitis (AD). The minimum EASI score is 0 (= normal) and the maximum EASI score is 72 (= very severe).
Time frame: Trial Week 24, Trial Week 33
Scoring Atopic Dermatitis (SCORAD) 90 response
Response is defined as an improvement from baseline of at least 90%. The Scoring Atopic Dermatitis (SCORAD) evaluates the extent and severity of eczema in atopic dermatitis (AD) based on affected body area and intensity of plaque characteristics.It comprises 3 areas: Area, Intensity and Subjective Symptoms. The final result range is between 0 (best result) and 103 (worst result).
Time frame: Trial Week 4, Trial Week 8, Trial Week 12, Trial Week 16
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Not enrolling at this site — choose another above.
Started Feb 2024 (actual). Primary completion is estimated for Nov 2026, 33 months after the start.
Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's planned 33 months is above that.
Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methotrexate